{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:56:10Z","timestamp":1790402170726,"version":"4.1.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":1803,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Thrombosis Research Institute"},{"name":"Bayer Pharma AG"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Heart failure (HF) and atrial fibrillation (AF) may coexist and influence each other. However, characteristics, anticoagulant treatment, and outcomes of contemporary AF patients with concurrent HF are ill-defined. This study analyses characteristics, treatment, and 2 year outcomes in newly diagnosed Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) patients with vs. without HF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>GARFIELD-AF is the world's largest observational AF patient study. At enrolment, 11 758 of 52 072 patients (22.6%) had HF; 76.3% were New York Heart Association class II\u2013III. Patients with HF had comparable demographics, blood pressure, and heart rate but more likely had permanent (15.6% vs. 11.9%) or persistent AF (18.9% vs. 13.8%), acute coronary syndromes (16.7% vs. 8.9%), vascular disease (40.8% vs. 20.2%), and moderate-to-severe chronic kidney disease (14.6% vs. 9.0%) than those without. Anticoagulant prescription was similar between the two groups. At 2 year follow-up, patients with HF showed a greater risk of all-cause mortality [hazard ratio (HR), 2.06; 95% confidence interval (CI), 1.91\u20132.21; P &amp;lt; 0.0001], cardiovascular mortality (HR, 2.91; 95% CI, 2.58\u20133.29; P &amp;lt; 0.0001), acute coronary syndromes (HR, 1.25; 95% CI, 1.02\u20131.52; P = 0.03), and stroke\/systemic embolism (HR, 1.24; 95% CI, 1.07\u20131.43; P = 0.0044). Major bleeding rate was comparable (adjusted HR, 1.00; 95% CI, 0.84\u20131.18; P = 0.968). Among patients without HF at baseline, incidence of new HF was low [0.69 (95% CI, 0.63\u20130.75) per 100 person-years], whereas propensity to develop worsening HF was higher in those with HF [1.62 (95% CI, 1.45\u20131.80) per 100 person-years].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with AF and HF have a high risk of all-cause and cardiovascular mortality and stroke\/systemic embolism and may develop worsening HF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13156","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T04:58:26Z","timestamp":1610686706000},"page":"1139-1149","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Characteristics, Treatment, and Outcomes of Newly Diagnosed Atrial Fibrillation Patients with Heart Failure: GARFIELD-AF"],"prefix":"10.1093","volume":"8","author":[{"given":"Giuseppe","family":"Ambrosio","sequence":"first","affiliation":[{"name":"Division of Cardiology, University of Perugia School of Medicine , Ospedale S. Maria della Misericordia, Via S. Andrea delle Fratte, Perugia, 06156 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. John","family":"Camm","sequence":"additional","affiliation":[{"name":"Cardiovascular Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St. George's, University of London and St George's University Hospitals NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Bassand","sequence":"additional","affiliation":[{"name":"Thrombosis Research Institute , London ,","place":["UK"]},{"name":"University of Besan\u00e7on , Besan\u00e7on ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Corbalan","sequence":"additional","affiliation":[{"name":"Catholic University School of Medicine , Santiago ,","place":["Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Kayani","sequence":"additional","affiliation":[{"name":"Thrombosis Research Institute , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erberto","family":"Carluccio","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Perugia School of Medicine , Ospedale S. Maria della Misericordia, Via S. Andrea delle Fratte, Perugia, 06156 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo G.","family":"Mantovani","sequence":"additional","affiliation":[{"name":"Center for Public Health Research (CESP), Postgraduate School of Hygiene and Preventive Medicine, University of Milan-Bicocca , Monza ,","place":["Italy"]},{"name":"Value-based Healthcare Unit, IRCCS Multimedica Research Hospital , Sesto San Giovanni ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Virdone","sequence":"additional","affiliation":[{"name":"Thrombosis Research Institute , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Kakkar","sequence":"additional","affiliation":[{"name":"Thrombosis Research Institute , London ,","place":["UK"]},{"name":"University College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the GARFIELD-AF Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,12]]},"reference":[{"key":"2026012115073429400_ehf213156-bib-0001","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10741-017-9657-9","article-title":"Pathophysiological and therapeutic implications in patients with atrial fibrillation and heart failure","volume":"23","author":"Hohendanner","year":"2018","journal-title":"Heart Fail Rev"},{"key":"2026012115073429400_ehf213156-bib-0002","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ijcard.2014.05.023","article-title":"Predictors of new onset atrial fibrillation in patients with heart failure","volume":"175","author":"Campbell","year":"2014","journal-title":"Int J Cardiol"},{"key":"2026012115073429400_ehf213156-bib-0003","first-page":"VI102","article-title":"The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group","volume":"87","author":"Carson","year":"1993","journal-title":"Circulation"},{"key":"2026012115073429400_ehf213156-bib-0004","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/ejhf.187","article-title":"The prognostic significance of atrial fibrillation in heart failure with a preserved and reduced left ventricular function: insights from a meta-analysis","volume":"16","author":"Cheng","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026012115073429400_ehf213156-bib-0005","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1053\/euhj.1999.2107","article-title":"Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure","volume":"21","author":"Crijns","year":"2000","journal-title":"Eur Heart J"},{"key":"2026012115073429400_ehf213156-bib-0006","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1016\/j.jacc.2006.01.060","article-title":"Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program","volume":"47","author":"Olsson","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026012115073429400_ehf213156-bib-0007","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/eurheartj\/ehi166","article-title":"Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET","volume":"26","author":"Swedberg","year":"2005","journal-title":"Eur Heart J"},{"key":"2026012115073429400_ehf213156-bib-0008","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ejheart.2006.01.015","article-title":"Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF Study","volume":"8","author":"van Veldhuisen","year":"2006","journal-title":"Eur J Heart Fail"},{"key":"2026012115073429400_ehf213156-bib-0009","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.jacc.2009.01.055","article-title":"Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation","volume":"53","author":"Nieuwlaat","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026012115073429400_ehf213156-bib-0010","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrcardio.2015.191","article-title":"Comorbidity of atrial fibrillation and heart failure","volume":"13","author":"Ling","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"2026012115073429400_ehf213156-bib-0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063479","article-title":"Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry","volume":"8","author":"Kakkar","year":"2013","journal-title":"PLoS ONE"},{"key":"2026012115073429400_ehf213156-bib-0012","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ahj.2011.09.011","article-title":"International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD)","volume":"163","author":"Kakkar","year":"2012","journal-title":"Am Heart J"},{"key":"2026012115073429400_ehf213156-bib-0013","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"2026012115073429400_ehf213156-bib-0014","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"2026012115073429400_ehf213156-bib-0015","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"2026012115073429400_ehf213156-bib-0016","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.ajkd.2014.01.416","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD","volume":"63","author":"Inker","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2026012115073429400_ehf213156-bib-0017","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ijcard.2018.04.093","article-title":"Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: the PREFER in AF-HF substudy","volume":"265","author":"Siller-Matula","year":"2018","journal-title":"Int J Cardiol"},{"key":"2026012115073429400_ehf213156-bib-0018","doi-asserted-by":"crossref","first-page":"2D","DOI":"10.1016\/S0002-9149(02)03373-8","article-title":"Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy","volume":"91","author":"Maisel","year":"2003","journal-title":"Am J Cardiol"},{"key":"2026012115073429400_ehf213156-bib-0019","first-page":"751","article-title":"Atrial fibrillation and heart failure: a review of the intersection of two cardiac epidemics","volume":"6","author":"Lee Park","year":"2013","journal-title":"J Atr Fibrillation"},{"key":"2026012115073429400_ehf213156-bib-0020","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jacc.2015.08.038","article-title":"Arrhythmia-induced cardiomyopathies: mechanisms, recognition, and management","volume":"66","author":"Gopinathannair","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026012115073429400_ehf213156-bib-0021","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.115.018614","article-title":"Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction","volume":"133","author":"Santhanakrishnan","year":"2016","journal-title":"Circulation"},{"key":"2026012115073429400_ehf213156-bib-0022","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/jamacardio.2018.4729","article-title":"Analysis of outcomes in ischemic vs nonischemic cardiomyopathy in patients with atrial fibrillation: a report from the GARFIELD-AF registry","volume":"4","author":"Corbalan","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2026012115073429400_ehf213156-bib-0023","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012115073429400_ehf213156-bib-0024","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1161\/STROKEAHA.111.628479","article-title":"Chronic heart failure and ischemic stroke","volume":"42","author":"Haeusler","year":"2011","journal-title":"Stroke"},{"key":"2026012115073429400_ehf213156-bib-0025","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2026012115073429400_ehf213156-bib-0026","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"2026012115073429400_ehf213156-bib-0027","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012115073429400_ehf213156-bib-0028","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012115073429400_ehf213156-bib-0029","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jchf.2016.09.016","article-title":"Predictors and prognostic implications of incident heart failure in patients with prevalent atrial fibrillation","volume":"5","author":"Pandey","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2026012115073429400_ehf213156-bib-0030","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1016\/j.jacc.2017.09.027","article-title":"Type of atrial fibrillation and outcomes in patients with heart failure and reduced ejection fraction","volume":"70","author":"Mogensen","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026012115073429400_ehf213156-bib-0031","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026012115073429400_ehf213156-bib-0032","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"2026012115073429400_ehf213156-bib-0033","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13156","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13156","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/2\/1139\/65926453\/eschf_8_2_1139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/2\/1139\/65926453\/eschf_8_2_1139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:09:28Z","timestamp":1769026168000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/8\/2\/1139\/8381856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,12]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,1,12]]},"published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13156","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4]]},"published":{"date-parts":[[2021,1,12]]},"assertion":[{"value":"2020-08-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}